UroMems Appoints Rinda Sama to Board Ahead of Clinical Trials for Innovative Incontinence Treatment

UroMems Welcomes Rinda Sama to Its Board of Directors

UroMems, a global leader in medical technology, recently announced the appointment of Rinda Sama, a seasoned executive with nearly two decades of experience in the medical device sector, to its board of directors. This strategic hire comes as UroMems gears up for critical clinical trials for their groundbreaking UroActive system, designed to combat stress urinary incontinence (SUI).

Rinda Sama brings a wealth of expertise from her notable career, including over a decade as Chief Operating Officer at Axonics, a fellow innovator in the field. During her tenure at Axonics, she was instrumental in streamlining operations and ensuring compliance with quality systems that ultimately led to obtaining FDA approval. Moreover, her role was pivotal during Axonics' recent acquisition by Boston Scientific, underscoring her profound impact on the company.

In a statement, Hamid Lamraoui, UroMems' co-founder and CEO, expressed enthusiasm over Sama's addition to the board. He stated, "Rinda's extensive background in medical technology, particularly her work with sacral neuromodulation therapies at Axonics, will be invaluable as we move into larger-scale clinical trials in the U.S. and Europe for UroActive. This product is set to be the first intelligent automated urinary sphincter designed for individuals experiencing SUI."

Sama highlighted her excitement about joining UroMems at such a pivotal time. She noted the similarities between UroMems and Axonics several years ago when Axonics embarked on developing innovative treatments in a space that had seen little advancement for a long time. "I see a tremendous opportunity for the UroActive system to transform the landscape of SUI treatment, just as Axonics did with their smart devices," she commented.

UroMems has recently achieved significant milestones in its R&D, including a successful $47 million funding round. This financial support was bolstered by impressive outcomes from a six-month multicenter human clinical study, which marked a significant advancement in the development of automated smart sphincters. Notably, the first woman treated with this innovative device responded positively, paving the way for future trials.

According to statistics, SUI affects around 40 million individuals in the United States and an additional 90 million across Europe. The condition not only impacts physical well-being but can also severely diminish quality of life, often leading to emotional distress, low self-esteem, and societal stigma.

About UroActive

UroActive represents a revolutionary step forward in the treatment of urinary sphincter insufficiency. It is the first active electronic artificial urinary sphincter implant designed to aid both men and women suffering from SUI. The technology utilizes a unique mechatronic platform that combines intelligent, digital, and robotic systems. This sophisticated approach allows the generation of personalized treatment algorithms generated from patient data, ensuring tailored care for each individual. The extensive technological platform of UroMems is backed by over 150 patents, focusing on overcoming current treatment limitations by enhancing patient safety, device performance, and surgical convenience.

As of now, UroActive has not yet received market approval from the FDA and is unavailable for sale in either the U.S. or Europe. For more information about UroMems and their innovative projects, visit uromems.com.